Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis

Myriam Khalili; Arnaud Bonnefoy; Dominique S Genest; Jérémy Quadri; Jean-Philippe Rioux; Stéphan Troyanov

doi:10.1016/j.ekir.2020.07.018

Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis

Kidney Int Rep. 2020 Jul 23;5(10):1690-1699. doi: 10.1016/j.ekir.2020.07.018. eCollection 2020 Oct.

Authors

Myriam Khalili¹, Arnaud Bonnefoy², Dominique S Genest¹, Jérémy Quadri², Jean-Philippe Rioux^{1

3}, Stéphan Troyanov^{1

3}

Affiliations

¹ Division of Nephrology, Hôpital du Sacré-Cœur de Montréal, Quebec, Canada.
² Division of Hematology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada.
³ Division of Nephrology, Hôtel-Dieu de St-Jérôme, Quebec, Canada.

Abstract

Introduction: Complement activation, inflammation, and fibrosis play central roles in the mechanisms of injury in autoimmune glomerulonephritis (GN) but they are seldom assessed in epidemiologic studies. The measurement of urinary biomarkers of these pathways of injury could parallel disease activity and add clinical value beyond proteinuria.

Methods: We performed a prospective cohort study of 100 patients with focal and segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy (IgAN), lupus nephritis (LN), anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV), and membranoproliferative GN (MPGN) followed for 33 (18-54) months. Repeated urinary samples were collected throughout their follow-up to determine proteinuria, urinary sC5b-9, monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-beta 1 (TGF-β1), expressed as creatinine ratios. We identified 177 periods of active and inactive disease based on current remission definitions for each disease.

Results: Urinary sC5b-9, MCP-1, and TGF-β1 were present in each disease. In periods leading to a remission, the reduction of urinary sC5b-9 was 91%, greater than for proteinuria with 76%. During inactive periods, those who did not experience a relapse maintained lower levels of biomarkers compared with those who relapsed. At that time, the increase in urinary sC5b-9 was significantly greater than the rise in proteinuria (8.5-fold increase compared with 3.2-fold) and urinary MCP-1 and TGF-β1. Using current remission definitions for each disease, thresholds for each biomarker were determined using receiver operating characteristic curves. Individuals who averaged levels below these cutoffs during their follow-up had better renal outcomes.

Conclusion: In autoimmune glomerular diseases, urinary sC5b-9, MCP-1, and TGF-β1 are present and parallel disease activity and outcomes. Urinary sC5b-9 appears to be a more discerning marker of immunologic remissions and relapses.

Keywords: MCP-1; TGF-β1; autoimmune glomerulonephritis; complement; sC5b-9; urinary biomarkers.